Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-7-[4-(3,5-Difluorobenzoyl)-1-Piperazinyl]-6-Fluoro-1,4-Dihydro-4-Oxo- is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound matters for its critical role as a key building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly within the fluoroquinolone antibiotic class. It is primarily needed by pharmaceutical R&D departments, fine chemical manufacturers, and contract research organizations (CROs) engaged in developing next-generation antimicrobial therapies and other specialized organic syntheses.

Application

• Pharmaceutical Intermediate: Serves as a crucial precursor in the synthesis of novel fluoroquinolone antibiotics and other therapeutic agents.
• Antimicrobial Research: Used in R&D for developing new compounds targeting bacterial DNA gyrase and topoisomerase IV enzymes.
• Organic Synthesis Building Block: Utilized in complex multi-step syntheses due to its reactive quinoline and piperazine moieties.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for cGMP production of clinical trial materials.
• Chemical Reference Standard: Acts as a high-purity standard for analytical method development and quality control in API manufacturing.
• Academic & Industrial Research: Employed in medicinal chemistry programs to explore structure-activity relationships (SAR) and new pharmacological targets.

Basic Information

Item	Details
Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-7-[4-(3,5-Difluorobenzoyl)-1-Piperazinyl]-6-Fluoro-1,4-Dihydro-4-Oxo-
CAS No.	1054010-94-4
Molecular Formula	C24H20F3N3O3
Molecular Weight	455.43 g/mol
Synonyms	1-Cyclopropyl-7-[4-(3,5-difluorobenzoyl)piperazin-1-yl]-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; WCK 771 Intermediate; 1-Cyclopropyl-6-fluoro-7-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid; Levonadifloxacin Intermediate; (1-Cyclopropyl-6-fluoro-7-{[4-(3,5-difluorobenzoyl)piperazin-1-yl]}-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid); Benzoic acid, 3,5-difluoro-, 4-(1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonyl)-1-piperazinyl]phenyl]methanone (9CI); WCK-771 related compound; Anti-MRSA quinoline intermediate.
EINECS	Contact for details

Quality Control

Our 3-Quinolinecarboxylic Acid derivative is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets the high standards required for pharmaceutical development. Certificates of Analysis (COA) with detailed chromatographic data are provided and can be tailored to meet specific client or regulatory requirements, supporting applications from research to cGMP manufacturing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). This compound is sensitive to fluoride/strong alkali conditions; ensure it is stored separately from such materials. For long-term storage, consider inert atmosphere conditions to maximize stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.